Plenary: Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s ◦ Favourable safety profile ◦ Well-tolerated over 24 Wks ◦ Improved ESSDAI, salivary flow, Igs ◦ May be first effective oral disease-modifying therapy for SS Dorner T Abs1113 https://t.co/FkgJpwKAJL #ACR22 @RheumNow https://t.co/znxMc27EBI

• Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a…

Biologics to treat gut microbiome dysbiosis?? In axSpA pts treated with bDMARDs for one year, gut microbiome resembled those of controls. Collinsella remained stable - possible biomarker? Abs#1162 @RheumNow #ACR22 #ACRBest https://t.co/vmQFJMpNPP

Singh @NamrataRheum et al. 27,421 RA patients, 8225 on b/tsDMARD. b/tsDMARDs did not increase risk of lymphoma. IR 1.68/1000PY (95% CI 1.5-1.9) on csDMARD vs IR 1.73/1000PY (95%CI 1.4-2.1) on b/tsDMARD. @RheumNow #ACR22 Abstr#1210 https://t.co/3Uvz3mvsGM https://t.co/6k3Vqb21KF

• Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs an…

Barroso-García et al. ADA vs IFX vs TCZ in severe ocular Behcets with refractory cystoid macular edema. Remission 76% (ADA), 60% (IFX), 67% (TCZ). @RheumNow #ACR22 Abstr#1564 https://t.co/pRVgIdGAGS https://t.co/gOb5wQ9pHv

• Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involveme…

BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing potentially pathogenic B-cell subsets. Abs 0978 #ACR22 @RheumNow https://t.co/Y798OAwtbt https://t.co/IfXOv67MLV

• Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shift…

Filho et al. Retrospective Brazilian study. ADA vs LEF in Takayasu arteritis. Comparable renission, relapses, steroid dose, ESR, CRP, imaging over median 15 weeks. More AEs in LEF but non-severe. @RheumNow #ACR22 Abstr#1553 https://t.co/499dUNmpUD https://t.co/AEk5cG7dc4

• Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Taka…

Ab1113 #ACR22 Remibrutinib (LOU064, BTK inhib) in Sjogren's Will there be new Rx for Sjo? T Dorner: 73 pts Ph2 BTK 100mg BID/100 QD/PBO Better ESSDAI at wk 24 (p=0.003) Unstim saliv flow: improved vs PBO, not stat signif Decreased CXCL13 chemokine PROs not improved @RheumNow https://t.co/hJp33JPpHt

DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ

• Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patie…

DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz

2nd Plenary Session! Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study) Improvement of ESSDAI, salivary flow and pathologically elevated Ig's Abs#1113 @RheumNow #ACR22 https://t.co/vdgxBPe6qd

We're used to originator-to-biosimilar switches. Widespread biosim use means we now see biosim-biosim switches (incl as second switch) DANBIO data retention good I see the hallmarks of nocebo still an issue I think we can all agree: ongoing education important #ACR22 @RheumNow https://t.co/6PcMfEEozk

Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M

Valero et al. Combined biologics in PsA. @RheumNow #ACR22 Abstr1044 https://t.co/7nNf0Ktf0M https://t.co/CIE9BnBFvx

• Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a…

#ACR22 Abstr#0826 2 years on since FDA approved #Tocilizumab in Adults Onset Still's Disease, real-world data from Japan affirmed its effectiveness and as a steroid-sparring agent @RheumNow https://t.co/jbmhEnGwXO